News Updates
More Articles
- The Pitfalls and Promise of Cell and Gene Therapy Development: A Time for Concerted Action
- “Not Just Checking a Box”: A Call to Rethink Patient Involvement in the EU
- From Cells to Animals and Back Again: The Shifting Landscape of Cancer Efficacy and Safety Models
- Addressing Inequity: Embedding Inclusion and Diversity in UK Clinical Trials
- The Next AI Revolution: Computer System Validation
Ensuring Data Privacy in EU Pharmacovigilance
All Marketing Authorization Holders (MAHs) in the EU must comply with post-marketing pharmacovigilance (PV) requirements, including reporting of adverse events (AEs), and simultaneously ensure that personal data are processed only where necessary and only where the parties involved assess this necessity at every stage of the PV process.